405554-89-4

Upstream product

• 405554-88-3 4-(2-phenyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)pyridine 
• 234766-97-3 4-(2-phenyl-1H-imidazol-4-yl)pyridine 
• 76513-69-4 (2-trimethylethylsilylethoxy)methyl chloride 
• 618-39-3 benzamidin 
• 5349-17-7 4-bromoacetylpyridine hydrobromide 

Downstream Products

• 1283092-12-5 methyl 4-(2-phenyl-4-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)benzoate 
• 1283092-18-1 4-[5-(4-nitrophenyl)-2-phenyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-4-yl]pyridine 
• 1283092-13-6 (4-(2-phenyl-4-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)phenyl)methanol 
• 1283092-14-7 4-(2-phenyl-4-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)benzyl methanesulfonate 
• 1283092-15-8 4-(5-(4-(azidomethyl)phenyl)-2-phenyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)pyridine 
• 1283092-16-9 (4-(2-phenyl-4-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)phenyl)methanamine 
• 1314263-94-9 3-(2-phenyl-4-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)aniline 
• 1314258-60-0 N-{2-chloro-5-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenyl}methanesulfonamide 
• 1314264-15-7 N-(3-(2-phenyl-4-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)phenyl)methanesulfonamide 
• 1314264-25-9 N-{2-chloro-5-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenyl}methanesulfonamide 
• 1314258-29-1 N-{3-[2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl]phenyl}ethane-1-sulfonamide 
• 1450018-72-0 3-methoxy-5-(2-phenyl-5-(pyridine-4-yl)-1H-imidazol-4-yl)pyridine-2-amine 
• 1283092-21-6 4-(2-phenyl-4-(pyridin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)benzoic acid 
• 1283091-28-0 4-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)aniline 

Relevant academic research and scientific papers

Novel Heterocyclic Compounds and Uses Thereof

New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

HETEROCYCLIC KINASE INHIBITORS

Described herein are compounds, pharmaceutical compositions and methods for the inhibition of kinase signaling mediated by the kinases A-RAF, B-RAF,C-RAF, p38, or GSK3β.. Said compounds, pharmaceutical compositions and methods have utility in the treatment of human disease and disorders.

RAF KINASE INHIBITORS

Described herein are compounds, pharmaceutical compositions and methods for the inhibition of RAF kinae mediated signaling. Said compounds, pharmaceutical compositions and methods have utility in the treatment of human disease and disorders.

NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF

New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

Imidazole derivatives as raf kinase inhibitors

Novel compounds (I) and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy wherein Ar is a group of formula a) or b).